Overview

INDV-2000 First in Human

Status:
Completed
Trial end date:
2021-04-12
Target enrollment:
Participant gender:
Summary
This study will be a single ascending dose (SAD) study conducted to identify the maximum tolerated dose (MTD). After completion of the SAD portion of the study and acceptable safety evaluation, a food-interaction, single-dose study under fed and fasted conditions will be conducted.
Phase:
Phase 1
Details
Lead Sponsor:
Indivior Inc.
Collaborator:
National Institute on Drug Abuse (NIDA)